UroVaxom

UroVaxom
Vaccine description
TargetEscherichia coli
Vaccine typeInactivated
Clinical data
Trade namesUroVaxom
Other namesOM-89; OM-8980
Routes of
administration		Oral (tablet)

UroVaxom (developmental code names OM-89, OM-8980) is a vaccine against urinary tract infections (UTIs). It is an extract of 18 strains of killed Escherichia coli administered as an oral tablet once daily for 3 months. The vaccine is marketed for use in the prevention of recurrent UTIs in some European countries. It was also being studied for treatment of prostatitis but was discontinued. UroVaxom was initially developed in the 1980s.

See also

References

  1. 1 2 Hughes T, Juliebø-Jones P, Saada L, Saeed K, Somani BK (December 2021). "Recurrent urinary tract infections in adults: a practical guide". British Journal of Hospital Medicine. 82 (12): 1–11. doi:10.12968/hmed.2021.0337. PMID 34983214.
  2. 1 2 3 4 O'Brien VP, Hannan TJ, Nielsen HV, Hultgren SJ (February 2016). "Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections". Microbiology Spectrum. 4 (1). doi:10.1128/microbiolspec.UTI-0013-2012. PMC 4887100. PMID 26999391.
  3. 1 2 3 4 "OM 8980". AdisInsight. 16 August 2022. Retrieved 26 February 2025.
  4. ↑ Prattley S, Geraghty R, Moore M, Somani BK (May 2020). "Role of Vaccines for Recurrent Urinary Tract Infections: A Systematic Review". European Urology Focus. 6 (3): 593–604. doi:10.1016/j.euf.2019.11.002. PMID 31806578.
  5. ↑ Huttner A, Gambillara V (October 2018). "The development and early clinical testing of the ExPEC4V conjugate vaccine against uropathogenic Escherichia coli". Clinical Microbiology and Infection. 24 (10): 1046–1050. doi:10.1016/j.cmi.2018.05.009. PMID 29803843.